The move by the EU’s four largest countries breaks through into several smaller member states – and marks a new crisis of confidence for it. Affordable vaccine That is seen as the best hope to accelerate COVID-19 vaccination around the developing world.
Experts insist that the vaccine is causing these reported clots and that there is no clear evidence that its regulators are investigating the cases. But the latest concerns follow earlier Scientists question How the company has communicated issues with it Safety and effectiveness Its vaccine came shortly before AstraZeneca expected results from a larger clinical trial that would determine whether the FDA approved the vaccine for use in the United States.
Vaccination breaks in Europe were triggered by reports of three hospital admissions, one of which resulted in the death of a patient who was vaccinated. Norway, And Another death in Denmark. In this Statement The European Medicines Agency, the European Union’s regulator, equivalent to the FDA, issued on March 11, reported that a total of 30 cases of “thromboembolic events” or blood clots had occurred in the 5 million people who received AstraZeneca shots. In the EU
“There is no indication that the vaccine caused these conditions, which are not listed as side effects with this vaccine,” the EMA said. “The EMA’s Safety Committee position … The benefits of the vaccine continue to outweigh its risks and the vaccine may continue to be delivered.”
AstraZeneca said there were a total of 37 reports of pulmonary embolism and deep vein thrombosis, both of which were due to blood clots because it was lower than expected from the general population.
“About 1 million people in the European Union and the United Kingdom have now received our vaccine, and the number of blood clots in this group is lower than expected in hundreds of cases,” said Ann Taylor, the agency’s chief medical officer. Statement Issued March 14.
And the World Health Organization Urges countries to continue using vaccinesEchoes that there is no evidence of blood clotting. WHO experts are meeting on Tuesday to discuss reports of blood clots.
But a handful of incidents are taking a break from some countries. According to German Health Minister Jens Spahan, seven rare cases have been reported, Cerebral venous sinus thrombosis (CVST), of the 1.6 million AstraZeneca vaccines given in Germany. The Paul Ehrlich Institute, part of the German health ministry, said Monday it was Concerned This condition was reported along with abnormal bleeding and a low count of blood platelets, which prevents clotting and bleeding.
The handful of cases still seen in Germany will be higher than expected, but it could be a statistical stimulus. “[T]The likelihood of such statistical clustering for a result is actually very high, even if no cause or effect is present, “said Paul Hunter, a public health expert at the University of East Anglia, in a comment distributed through the UK’s Science Media Center.
The EMA is meeting on Tuesday to discuss concerns about blood clots and its conclusion is expected to be released on Thursday. Long-term vaccination breaks could be a worrying prospect, as COVID-19 cases are on the rise again in several EU countries – Italy is experiencing an experience. Particularly worrying encouragement – The more contagious forms spread.
Experts who contacted BuzzFeed News said there was not enough evidence to make a clear decision about whether the vaccine was frozen without the patients knowing more about the case. “We would like to know the age of the cases, their previous treatment history and the conditions that may have caused the risk or risk of bleeding,” said Orly Wardeni, a cardiac health specialist and pharmacist at the University of Minnesota.
“It simply came to our notice then. If it’s vaccine-related and if it’s not ubiquitous, the most likely explanation could be a production batch issue, “BuzzFeed News, a vicologist at Vale Cornell Medical College in New York who is working on vaccine development, told BuzzFeed News. Including AustriaYes, yes Especially off vaccination From special batches of Astragenica vaccine)
The latest concerns are about the stumbling block of a single series of AstraZeneca CVD-19 vaccines made at Oxford University. Back in November, AstraZeneca claimed one Press release Its vaccine was 70% effective overall and can be up to 90% effective if given half the dose for the first of the two shots. But many scientists There was suspicion, Especially after the drug company acknowledged that this regime is a Wrong calculated dose. AstraZeneca later added to this confusion To change its interpretation Starting from dosing to lengthen between two doses for 90% effectiveness.
Another deadly setback came in February, when tests in South Africa showed the vaccine. Was not effective Against the more contagious variant of the coronavirus infected there. South Africa abruptly discontinued plans to use the AstraZeneca vaccine and replaced it with vaccines developed by Johnson & Johnson and Pfizer / Bioentech.
Scientists are now waiting for the results Big test The FDA of the AstraZeneca vaccine, which is administered in the United States and other countries, will be the main basis for the agency’s application for the vaccine to be approved. However, some experts have wondered if adding AstraZeneca to the arsenal of vaccines used in the United States would create more problems. Anti-waxers can swallow negative propaganda To reduce the larger vaccination drive around it.
“Is there really a filled niche? Would that be credible enough? Or is it going to be another headache? Moore said.
Children’s Health Protection, an organization which Paddled Incorrect information And Conspiracy theory About the vaccine for years, already there Highlights News that several European countries are stopping the use of this vaccine.
Where the vaccine can make a huge difference is in the developing world, especially in Africa, where there is a vaccine rollout. Back to back. The Biden administration is already under pressure to donate doses of the AstraZeneca vaccine to poor countries. The New York Times reported March 11, Kovacs – In collaboration with WHO, Coalition for Epidemic Preparedness Innovations and Gavi, Vaccine Alliance to provide affordable vaccines to poor countries – Depending on the use of the AstraZeneca vaccine To supply millions of doses worldwide.
“Safety is our main concern: we know that national authorities and the WHO are closely monitoring the situation and the COVX facility will follow their guidance and recommendations,” a Gavi spokesman told BuzzFeed News. “There is currently no causal link between vaccines and thromboembolic events in individuals, and the vaccine remains an important and effective public health tool in the fight against this epidemic.”